Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

• Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deactivation of treatment, and reproducible upon reactivation following a washout period
• Simultaneous peer-reviewed publication of AVIM therapy mechanistic and clinical results
• Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to develop and commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annually
• AVIM therapy has FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients

Excerpt from the Press Release:

NEW HOPE, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced new data from its AVIM therapy program, presented at the HRX Live 2025 Meeting, in Atlanta, GA, demonstrating that the blood pressure-lowering effects of AVIM therapy may be sustained for years after activation, are reversible with no evidence of rebound hypertension or blood pressure exceeding initial baseline values, and can be restored upon reactivation. These data further support AVIM therapy’s potential role as a controllable, programmable, and durable device-based therapy for uncontrolled hypertension.

Avi Fischer, MD, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed presented an overview of mechanistic and clinical data supporting the potential role of AVIM therapy for the treatment of uncontrolled hypertension during the Innovation Summit at HRX Live 2025, as part of the session titled “Pacing and Implanted Device Therapy.” His presentation coincided with the simultaneous peer-reviewed publication of these results in Heart Rhythm O₂, titled, “Atrioventricular Interval Modulation (AVIM) for Management of Hypertension.”

Dr. Fischer stated, “These results add to the growing body of promising data supporting AVIM therapy’s potential role as a novel and programmable treatment option for patients whose hypertension remains uncontrolled despite existing medical regimens.

Click the button below to read the entire Press Release:

Continue Reading The Press Release